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Percutaneous Placement of Self-Expandable Metallic 
Stents in Patients with Obstructive Jaundice Secondary 
to Metastatic Gastric Cancer after Gastrectomy
Hyun Pyo Hong, MD1, 5, Tae-Seok Seo, MD2, In-Ho Cha, MD2, Jung Rim Yu, MD2, Young Jae Mok, MD3,  
Joo Hyeong Oh, MD4, Se Hwan Kwon, MD4, Sam Soo Kim, MD5, Seung Kwon Kim, MD6
1Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746, Korea; Departments of 
2Radiology and 3Gastroenterologic Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul 152-703, Korea; 
4Department of Radiology, Kyung Hee University Medical Center, Seoul 130-872, Korea; 5Department of Radiology, Kangwon National University 
College of Medicine, Chuncheon 200-722, Korea; 6Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University 
School of Medicine, St. Louis, MO 63110, USA
Objective: To evaluate the outcomes of patients undergoing percutaneous placements of a biliary stent for obstructive 
jaundice secondary to metastatic gastric cancer after gastrectomy. 
Materials and Methods: Fifty patients (mean age, 62.4 years; range, 27-86 years) who underwent percutaneous placements 
of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy were included. The 
technical success rate, clinical success rate, complication rate, stent patency, patient survival and factors associated with 
stent patency were being evaluated.
Results: The median interval between the gastrectomy and stent placement was 23.1 months (range, 3.9-94.6 months). 
The 50 patients received a total of 65 stents without any major procedure-related complications. Technical success was 
achieved in all patients. The mean total serum bilirubin level, which had been 7.19 mg/dL ± 6.8 before stent insertion, 
decreased to 4.58 mg/dL ± 5.4 during the first week of follow-up (p < 0.001). Clinical success was achieved in 42 patients 
(84%). Percutaneous transhepatic biliary drainage catheters were removed from 45 patients (90%). Infectious complications 
were noted in two patients (4%), and stent malfunction occurred in seven patients (14%). The median stent patency was 
233 ± 99 days, and the median patient survival was 179 ± 83 days. Total serum bilirubin level after stenting was an 
independent factor for stent patency (p = 0.009).
Conclusion: Percutaneous transhepatic placement of a biliary stent for obstructive jaundice secondary to metastatic gastric 
cancer after gastrectomy is a technically feasible and clinically effective palliative procedure.
Index terms: Biliary tract, malignant obstruction; Biliary tract, interventional procedures; Prosthesis, stent; Gastric carcinoma
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INTRODUCTION
Gastric cancer is the second leading cause of cancer-
related deaths in the world and the increasing incidence 
of gastric cancers is being observed in association with 
the increasing life-span of the general population (1). 
Obstructive jaundice is an uncommon manifestation 
of metastases from gastric cancer and its incidence is 
reported to be 1.3-2.3% (2-4). Chemotherapy, surgical 
http://dx.doi.org/10.3348/kjr.2013.14.5.789
pISSN 1229-6929 · eISSN 2005-8330
Original Article | Intervention
790
Hong et al.
Korean J Radiol 14(5), Sep/Oct 2013 kjronline.org
decompression, interventional decompression, and 
radiation treatment are usually recommended with 
palliative intent (5). Although the main treatment for 
gastric cancer metastases is chemotherapy, jaundice is 
one of the contraindications for chemotherapy, and the 
prognosis for these patients is generally poor (6). Therefore, 
biliary drainage is needed to relieve jaundice, prevent 
complications, start chemotherapy and improve prognosis. 
Percutaneous or endoscopic self-expandable metallic 
stent insertion is a well-established method for palliating 
a patient with an inoperative malignant biliary obstruction 
due to hepatic, pancreatic, and gallbladder carcinoma and 
metastatic lymphadenopathy (7-11). Although there have 
been many studies on the outcomes after palliative stenting 
for unresectable tumors, less is known about the outcomes 
after stenting for obstructive jaundice secondary to gastric 
cancer after resection. As endoscopic stenting is usually 
difficult in patients with Billroth-II reconstruction or Roux-
en-Y esopohagojejunostomy, the endoscopic approach is not 
usually used in these patients. To our knowledge, there have 
been few studies on the outcomes of percutaneous stents 
placement for obstructive jaundice secondary to metastatic 
gastric cancer and these studies included inoperable gastric 
cancers (6, 12, 13). A large study is required to determine 
the role of percutaneous stenting as a palliative treatment 
in patients who were treated with gastrectomy. Therefore, 
the purpose of this study is to evaluate the outcomes of 
percutaneous stents placement for obstructive jaundice 
secondary to metastatic gastric cancers after gastrectomy. 
MATERIALS AND METHODS
Patient Population
We collected data from three referral hospitals. This 
retrospective study was approved by the institutional 
review boards of the three participating hospitals and the 
requirement for individual patient consent was waived for 
this study. We searched the patients who had percutaneous 
stenting and gastrectomy from medical record or database. 
Patients with obstructive jaundice secondary to afferent 
loop syndromes or patients with extensive liver metastasis 
causing liver failures were excluded. Patients whose primary 
tumor was treated by endoscopy were also excluded. 
From January 2003 to March 2010, 50 patients who had 
obstructive jaundice secondary to metastatic gastric cancer 
after gastrectomy underwent percutaneous placement 
of a self-expandable metallic stent via a percutaneous 
transhepatic biliary drainage (PTBD) tract. The patients 
included 31 men and 19 women (mean age: 62.4 years, age 
range: 27-86 years). All gastric tumors were histologically 
confirmed as malignant advanced gastric cancers. All 
diagnoses of cancer metastasis and obstructive jaundice 
were based on clinical findings in addition to computed 
tomography (CT), cholangiogram findings and serum 
bilirubin levels (14, 15). 
 
PTBD, Stent Placement and Follow-up 
Percutaneous transhepatic biliary drainage procedures 
were performed to treat obstructive jaundice and provide 
access for the placement of a biliary stent. Broad spectrum 
antibiotics were given intravenously 24 hours before each 
PTBD procedure and for at least 48 hours afterwards (16). 
Procedures were performed with the patient under local 
anesthesia with 2% lidocaine hydrochloride and intravenous 
conscious sedation. Under the guidance of ultrasonography 
and fluoroscopy, unilateral PTBD was performed in 45 
patients (right, n = 29; left, n = 16) and bilateral PTBD was 
performed in 5 patients. 
All placement of a biliary stent was performed 2-42 days 
(mean, 14.35 days) after PTBD for decompressions of the 
bile duct, improvements of cholangitis, and restorations 
of liver function. Before placement of the biliary stents, 
cholangiograms were obtained by injecting iodine contrast 
media through a previously inserted PTBD catheter to 
assess the decompression, stenosis site and exact anatomy 
of the bile duct. After inserting the 0.035-inch guide 
wire, the PTBD catheter was removed and a 5 Fr catheter 
was advanced through the PTBD tract. The guide wire 
and catheter were advanced across the stenosis to the 
duodenum. The stenosis was opacified with injections of 
contrast media through the catheter and the length was 
measured. Balloon dilation of the stenosis before stent 
placement was not routinely performed unless the stenosis 
was tight. Balloon dilation was performed before stent 
placement in five patients. The stent was placed to lie 
across the stenosis. Stents were 3-4 cm longer than the 
stricture to cover it completely including the proximal and 
distal adjacent portions. Stent diameters ranged from 8 mm 
to 10 mm and the average stent length was 6.6 cm (range: 
4 to 10 cm). 
Fifty patients received a total of 65 metallic stents. We 
used various kinds of self-expanding metallic stents in this 
study including Hercules DH biliary stents (S&G Biotech, 
Seongnam, Korea) (n = 26), BONA stents (Standard Sci-Tech 
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Inc., Seoul, Korea) (n = 19), Hanaro stents (MI Tech, Seoul, 
Korea) (n = 8), Wallstents (Boston Scientific, Natick, MA, 
USA) (n = 4), GD stents (TaeWoong Medical, Gimpo, Korea) (n 
= 3), Sentinol stents (Boston Scientific) (n = 3), and Zilver 
stents (Cook, Bloomington, IN, USA) (n = 2). The GD stent 
is a partially covered stent and other stents are uncovered 
stents. 
Unilateral stenting was performed in forty patients (80%) 
with the placement of one or two stents. In five patients, 
separate stents were placed in the hepatic hilum to achieve 
a Y-configuration. A T-configuration was achieved in five 
patients using BONA stents with a mesh through technique 
(17, 18). At the time of the initial stent placement, the 
50 enrolled patients received a total of 62 stents. An 
additional 3 stents were inserted to treat tumor ingrowths 
in three patients. 
After the stents placement, an 8.5 Fr drainage catheter 
(Cook, Bloomington, IN or Sungwon medical, Cheongju, 
Korea) was placed in the duct proximal to the stent and 
cholangiograms were obtained to check the immediate 
stent patency. After 2-3 days of waiting for spontaneous 
stent expansions, follow-up cholangiograms were obtained. 
Symptoms of biliary obstruction such as fever, pain, bile 
leakage, and serum bilirubin level were also checked before 
follow-up cholangiograms from medical records. If stent 
function was appropriate with spontaneous passages of 
contrast media to the duodenum, dilatation of the bile 
ducts was improved on the follow-up cholangiogram 
and there was no symptom of biliary obstruction, thus, 
the drainage catheter was removed after PTBD catheter 
clamping for one day. In cases with symptoms of biliary 
obstruction, the PTBD drainage was maintained.
The patients were followed-up as outpatients during the 
follow-up period. Serum bilirubin levels were checked to 
determine whether biliary drainage was impeded. If patients 
had obvious jaundice or a higher bilirubin level than before 
stent placements, the stent was assumed to be obstructed. 
In cases of recurrent jaundice or increased bilirubin levels, 
patients were evaluated with CT. CT scans showed dilation 
of the intrahepatic duct and the enhancement of inside the 
stent which is interpreted as tissue growths (19). Stent 
occlusion was diagnosed according to clinical, laboratory, 
and radiologic findings. In the case of stent occlusion, we 
performed decompressions of the bile duct by secondary 
percutaneous interventional procedures depending on the 
condition of the patients (20). 
 
Definitions and Study Endpoints 
Technical success was defined as placement of the stents 
by providing continuous drainage of bile without any 
major procedure-related complications. Clinical success 
was defined as a > 30% decrease in the serum bilirubin 
level relative to the baseline value (i.e., before stent 
insertion) within the first week after stent insertions (21). 
In cases where serum bilirubin level was normalized after 
PTBD, clinical success was defined as maintenance of the 
serum bilirubin level within the normal range after stent 
placements. 
Procedural complications were classified either as major 
or minor according to the reporting standards of the Society 
of Interventional Radiology (22). Major complications result 
in admissions to a hospital for therapy, an unexpected 
increase in the level of care, prolonged hospitalization, 
permanent adverse sequelae, or death. Minor complications 
resulting in no sequelae may require a short hospital stay 
for observation. 
Cholangitis was defined as recurrent episodes of 
inexplicable fever. Stent patency was defined as the time 
interval between initial stent placement and recurrence 
of obstruction. At the time of death, a stent was assumed 
to be patent if the patient had normal or only mildly 
elevated serum bilirubin levels (< 3 mg/dL). If the 
patients had obvious jaundice or higher serum bilirubin 
levels as compared to before the stent placement at the 
time of death, then the stent was assumed to have been 
obstructed. 
We evaluated the characteristics of primary gastric cancers 
and malignant biliary obstructions. Also, we evaluated the 
technical success rates, clinical success rates, complication 
rates, stents patency and patient survivals. The serum 
bilirubin levels before and during the follow-up period were 
statistically analyzed using the Paired-sample t test with 
PASW Statistics software (version 17.0; SPSS Inc., Chicago, 
IL, USA). The stent patency and patient survival with 95% 
confidence intervals (CIs) were calculated using the Kaplan-
Meier survival (life-table) analysis. The following variables 
were analyzed: gender, histology of previous gastrectomy, 
serosal invasion, lymph node metastasis of primary gastric 
cancer, hepatic metastasis after gastrectomy, level of biliary 
stenosis, stent configuration, total serum bilirubin after 
stenting, chemotherapy after stenting. We used univariate 
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RESULTS
Thirty-five patients (70%) had undergone subtotal 
gastrectomy and Billroth type II procedures while fifteen 
patients (30%) underwent total gastrectomy and Roux-en Y 
procedures. In 33 patients (66%), the primary carcinomas 
were located either in the pylorus or in the antrum with or 
without involvements of the stomach. In 17 patients (34%), 
the primary carcinomas were located either in the body or 
in the fundus (Table 1). 
The mean interval from surgery to PTBD was 27.5 months 
(range, 3.9-94.6 months). The mean total serum bilirubin 
level before PTBD was 15.24 mg/dL. All patients had 
node metastases. CT showed bile duct dilation and lymph 
nodes in the hepatoduodenal ligament and retropancreatic 
portion. Eleven patients (22%) had hepatic metastasis. 
Stenoses were diagnosed on CT and cholangiogram after 
PTBD and before biliary stent placement. Main level of 
stenoses were located at the common hepatic duct in 23 
patients (46%), proximal common bile duct in 16 patients 
(32%) and the distal common bile duct in 11 patients (22%) 
on cholangiogram. Among 23 patients who had stenosis in 
the common hepatic duct, 10 patients also had stenosis at 
the hilum (Table 2).
Technical success was achieved in all 50 patients. The 
mean total serum bilirubin level, which was 7.19 mg/dL 
± 6.8 before stent insertion, decreased to 4.58 mg/dL ± 
5.4 during the first week of follow-up, and this difference 
was statistically significant (p < 0.001). Clinical success 
was achieved in 42 of 50 patients (84%). Among the eight 
patients, who didn’t achieve clinical success, total serum 
bilirubin was increased after stent insertions in 5 patients 
and total serum bilirubin was mild decreased in 3 patients. 
In thirty patients (60%), total serum bilirubin level 
decreased ≤ 2 mg/dL after stenting. Forty-five patients 
(90%) showed a decrease in total serum bilirubin levels 
within the first week after stent placement. The PTBD 
catheter could be removed in these 45 patients because the 
stents were patented on cholangiogram acquired 2-3 day 
after stent insertions and there were no symptoms of biliary 
obstruction (Fig. 1). One patient wanted the drain catheter 
to be removed despite clinical failures and died 30 days 
later due to disease progressions. In other four patients, the 
PTBD catheter could not be removed due to clinical failures. 
PTBD catheter was kept and changed to prevent cholangitis. 
Among forty-two patients who achieved clinical successes, 
twenty-two patients (53%) were treated by chemotherapy 
after stent insertions. Other twenty patients didn’t receive 
chemotherapy due to disease progressions, poor conditions 
or denials for further treatment. Forty-seven patients (94%) 
were discharged from hospital after stent placement. Three 
patients died during hospitalization (mean: 18 days, range: 
3-32 days): two died due to disease progressions, and one 
secondary to pneumonia. 
There were no major procedure-related complications. 
In one patient who underwent a subtotal gastrectomy and 
Billroth type II procedure, a sludge material was noted in 
the CBD on the follow-up cholangiogram; however, this 
patient was managed conservatively and the catheter was 
being removed. Complications were noted in nine patients 
(18%) during the follow-up period. Infectious complications 
including cholecystitis and hepatic abscess was noted in 
two patients (4%) (mean: 151 days, range: 38-264 days), 
who were treated with percutaneous cholecystostomy and 
percutaneous hepatic abscess drainage. Two hundred sixty-
Table 1. Characteristics of Primary Gastric Cancer
Variable n %
Location of primary tumor
    Upper 1/2 17 34
    Lower 1/2 33 66
Macroscopic type
    Borrmann type 1 2 4
    Borrmann type 2 7 14
    Borrmann type 3 36 72
    Borrmann type 4 5 10
Histologic type
    Differentiated 45 90
    Signet ring cell 5 10
Serosal invasion
    No 20 40
    Yes 30 60
Lymph node metastasis
    No 4 8
    Yes 46 92
Previous gastrectomy
    Total gastrectomy 15 30
    Subtotal gastrectomy 35 70
Table 2. Characteristics of Malignant Biliary Obstruction
Variables n %
Main level of obstruction
    Common hepatic duct, hilum 23 46
    Proximal common bile duct 16 32
    Distal common bile duct 11 22
Hepatic metastasis 11 22
793
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four days after the stent placements, about 3 cm sized, left 
lateral segmental hepatic abscess developed in one patient 
who placed the stent through right PTBD tract. Recurrent 
jaundice was noted in seven patients (14%) after a mean of 
243.9 days (range: 56-635 days); all showed increased total 
serum bilirubin levels, intrahepatic ductal dilation, and 
enhancements inside the stent on CT scans. These seven 
patients were treated by PTBD, and second biliary stent was 
placed in three patients. 
The median and mean overall stent patency period was 
233 ± 99 days (95% CI, 38-427 days) and 286 ± 49 days 
(95% CI, 190-382 days), respectively. Univariate log rank 
analysis showed that total serum bilirubin level after 
stenting (p < 0.001) and chemotherapy after stenting (p 
= 0.002) were significantly associated with stent patency. 
Multiple Cox’s proportional hazard regression analysis 
showed total serum bilirubin level after stenting (p = 
0.009) was independent predictor of stent patency. Median 
A B C
Fig. 1. Sixty four-year-old female with obstructive jaundice resulting from gastric cancer after gastrectomy. 
A. Cholangiogram via left PTBD tract shows severe stricture at distal common bile duct. B. Guide wire was passed into duodenum and partially 
covered stent was inserted into common bile duct. C. Cholaniogram obtained three days after stent placement demonstrating further expansion 
of stent and good passage of contrast media. PTBD = percutaneous transhepatic biliary drainage
Fig. 2. Kaplan-Meier analysis of stent patency and patient survival. 
A. Kaplan-Meier analysis of primary stent patency. Median stent patency time was 233 ± 99 days (95% CI, 38-427 days). B. Kaplan-Meier analysis 
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stent patency period was significantly longer in patients 
with total serum bilirubin level ≤ 2 mg/dL (309 days; 95% 
CI, 119-498 days) compared to in > 2 mg/dL (59 days; 
95% CI, 43-75 days) after stenting. During the follow-up 
period, 25 patients died 3-710 days after stent placements. 
Among these 25 patients, 12 patients had normal or mildly 
elevated serum bilirubin levels (< 3 mg/dL). The median 
and mean of overall patient survival period was 179 ± 83 
days (95% CI, 16-342 days) and 274 ± 47 days (95% CI, 
181-367 days), respectively (Figs. 2, 3).
DISCUSSION
Although malignant biliary obstruction is an uncommon 
complication of gastric cancer, metastatic gastric cancer 
is the most frequent cause of metastatic obstructive 
jaundice (50%), followed by colon cancer (20%), breast 
cancer and melanoma (6, 23). Metastatic lymphadenopathy 
along the hepatoduodenal ligament is one of the main 
causes of biliary obstruction of gastric cancer, and its 
most common site is around the cystic duct. Standard D2 
lymph node dissection does not remove lymph nodes along 
the hepatoduodenal ligament. Two-thirds of such node 
metastases causing malignant biliary obstructions derived 
from gastric cancer in the antrum are located closely to 
the hepatoduodenal ligament. Direct invasion of recurrent 
gastric cancer also causes obstructive jaundice. During 
balloon dilation or stent insertion, eccentric smooth round 
or oval-shaped defects on the right lateral wall of the bile 
duct were commonly noted and this finding was due to 
extrinsic compressions from enlarged lymph nodes (15). In 
our study, 66% of patients had gastric cancer located in the 
lower 1/2 of the stomach, while bile duct stenoses were 
located at the common hepatic duct and proximal common 
bile duct in 78% of patients.
The surgical approach to malignant biliary obstruction is 
less applicable to biliary obstruction caused by metastatic 
tumors to the porta hepatis with extrinsic obstruction. 
Palliative bypass can prolong patient survival if properly 
performed. Two studies have shown that surgical treatment 
is associated with higher postoperative mortality, morbidity 
and a longer hospital stay than non-surgical drainages 
(24, 25). Endoscopic retrograde cholangiography (ERCP) 
is usually difficult in these patients because of a distorted 
bowel loop due to the Billroth II reconstruction or Roux-
en-Y esophagojejunostomy (26, 27). Afferent loop 
perforation is a specific complication of ERCP in these 
patients and these patients have a mortality rate varying 
from 0.7-5% (27). Therefore, we use PTBD as an initial 
treatment for patients with malignant biliary obstruction 
caused by metastatic gastric cancers. Although PTBD is 
expected to improve obstructive jaundice and drain the 
infected bile, it could also be associated with catheter-
related complications and lead to a deteriorating quality 
of life due to difficulties maintaining an external catheter 
and the need for regular catheter changes. Frequently 
encountered complications of PTBD are catheter 
dislodgement, cholangitis, and bile leakage (3, 28). Self-
expandable metallic stents provide more comfort than PTBD. 
Although there have been many studies of percutaneous 
stent placement for malignant biliary obstruction, studies of 
stent placement for obstructive jaundice caused by gastric 
cancer after limited gastrectomy (6, 12). 
The clinical success in our study is comparable to that in 
previous studies that focused on PTBD efficacy for palliative 
treatment (4, 12). Migita et al. (12) reported significant 
serum bilirubin decreases in 76% of the patients after 
PTBD. After the intervention, performance status improved 
in 68% of patients; however, 45% of patients could not 
be discharged from the hospital after the intervention for 
progressions of the underlying malignancy or jaundice. In 
our study, 90% of PTBD catheters could be removed and 
94% of our patients were discharged from the hospital after 
stent insertions. These results reveal that percutaneous 
Fig. 3. Multiple Cox’s regression analysis of stent patency. 
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stent placement for obstructive jaundice resulting from 
gastric cancer after gastrectomy is an effective palliative 
treatment. Gwon et al. (13) reported their experience of 
palliative treatment in 117 patients with malignant biliary 
obstruction caused by metastatic gastric cancer. In patients 
who had previously undergone gastrectomy for primary 
gastric cancer, the median interval between previous 
gastrectomy and onset of biliary obstruction was 26 months. 
Clinical success was 91% of 54 patients who underwent 
stent placements. Median stent patency time was 351 days. 
Among 54 patients who underwent stenting, there were 
patients who did not undergo gastrectomy. They didn’t 
find significant factors associated with stent patency. Our 
study only included patients who underwent gastrectomy. 
Percutaneous stenting was an effective palliative treatment 
and total serum bilirubin level after stenting was an 
independent predictor of stent patency. 
The purpose of percutaneous stenting for the treatment 
of obstructive jaundice is not only to improve jaundice, 
but also to give the patients an opportunity to receive 
palliative treatments such as systemic chemotherapy. Many 
systemic chemotherapy drugs require intact mechanisms of 
bile excretion to prevent toxicity. Twenty-two of the fifty 
patients (44%) who had a significant decrease in serum 
bilirubin level after stent placement received chemotherapy. 
Previous studies suggested that the use of chemotherapy 
after PTBD or stenting might prolong the survival of 
patients with obstructive jaundices caused by the local 
recurrence of gastric cancers (4, 12, 13).
There were no major procedure-related complications 
in our study. During the follow-up period, complications 
were noted in nine patients (18%). Cholecystitis and 
hepatic abscess were noted in two patients (4%). Recurrent 
jaundices and stent malfunctions were noted in seven 
patients (14%). These seven patients were treated by PTBD 
and a second biliary stent was placed in three patients. 
Previous studies reported that 7-30% of patients who 
underwent biliary stenting for palliation had complications 
and 14-25% of patients had recurrent symptoms of jaundice 
during the follow-up periods (29-31). Our results are 
comparable to those described in the studies. 
The stent patency and patient survival period in our 
study were better than those of previous studies on 
cholangiocarcinoma, gallbladder carcinoma, and pancreatic 
carcinoma (32, 33). However, making comparisons to 
previous studies is difficult because patients were treated 
at a different stage, and each tumor had a different 
histological type and biological behavior. Yet, the response 
to chemotherapy in our patients may have improved the 
survival period. Thirty-nine patients (78%) had stenoses 
at the common hepatic duct and proximal common bile 
duct mainly due to extrinsic compressions by malignant 
lymphadenopathy. These extrinsic compressive lesions may 
have responded better to biliary stent placements, and 
thus, may have improved stent patency. A larger study is 
needed to identify independent factors associated with 
stent patency and patient survival rates. 
There are several limitations to our study. First, this 
was a retrospective study. Second, this was a multicenter 
study with unconvered or partially covered types of stents 
used, which may have influenced stent patency. Third, 
gastric cancer recurrence was not confirmed histologically 
because reoperation or endoscopic biopsy for nodes in 
the hepatoduodenal ligament portion was very difficult. 
Jaundice was diagnosed during follow-up after gastrectomy 
due to the cancer, and mean interval from surgery to PTBD 
was 27.5 months. Imaging findings, clinical symptoms and 
laboratory findings were compatible with gastric cancer 
metastasis. 
In conclusion, percutaneous transhepatic placement of a 
biliary stent for obstructive jaundice caused by metastatic 
gastric cancer after a gastrectomy is a technically feasible, 
safe, and clinically effective palliative procedure. Total 
serum bilirubin level after stenting was an independent 
factor for stent patency. 
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